Clinical Laboratory Improvement Advisory Committee (CLIAC), 39879 [2011-17009]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 130 / Thursday, July 7, 2011 / Notices
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–16991 Filed 7–6–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
sroberts on DSK5SPTVN1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Times and Dates: 8:30 a.m.–5 p.m., August
31, 2011.
8:30 a.m.–12 p.m., September 1, 2011.
Place: CDC, 1600 Clifton Road, NE., Tom
Harkin Global Communications Center,
Building 19, Room 232, Auditorium B,
Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 100 people.
Purpose: This Committee is charged with
providing scientific and technical advice and
guidance to the Secretary of Health and
Human Services, the Assistant Secretary for
Health, and the Director, CDC, regarding the
need for, and the nature of, revisions to the
standards under which clinical laboratories
are regulated; the impact on medical and
laboratory practice of proposed revisions to
the standards; and the modification of the
standards to accommodate technological
advances.
Matters to be Discussed: The agenda will
include agency updates from the CDC, the
Centers for Medicare & Medicaid Services
(CMS), and the Food and Drug
Administration (FDA); presentations and
discussions on the laboratory’s role in the
development and use of electronic health
records, electronic laboratory reporting for
notifiable diseases, and meaningful use; and
presentations and discussion on current
practices in gynecologic cytology testing.
Agenda items are subject to change as
priorities dictate.
Online Registration Required: In order to
expedite the security clearance process at the
CDC Roybal Campus located on Clifton Road,
all CLIAC attendees are required to register
for the meeting online at least 14 days in
advance at https://www.cdc.gov/cliac/
default.aspx by clicking the ‘‘Register for a
Meeting’’ link and completing all forms
according to the instructions given. Please
complete all the required fields before
submitting your registration and submit no
later than August 16, 2011.
Providing Oral or Written Comments: It is
the policy of CLIAC to accept written public
comments and provide a brief period for oral
public comments whenever possible. Oral
Comments: In general, each individual or
VerDate Mar<15>2010
16:26 Jul 06, 2011
Jkt 223001
group requesting to make an oral
presentation will be limited to a total time of
five minutes (unless otherwise indicated).
Speakers must also submit their comments in
writing for inclusion in the meeting’s
Summary Report. To assure adequate time is
scheduled for public comments, individuals
or groups planning to make an oral
presentation should, when possible, notify
the contact person below at least one week
prior to the meeting date. Written Comments:
For individuals or groups unable to attend
the meeting, CLIAC accepts written
comments until the date of the meeting
(unless otherwise stated); however, it is
requested that comments be submitted at
least one week prior to the meeting date so
that the comments may be made available to
the Committee for their consideration and
public distribution. Written comments, one
hard copy with original signature, should be
provided to the contact person below.
Written comments will be included in the
meeting’s Summary Report.
Contact Person for Additional Information:
Nancy Anderson, Chief, Laboratory Practice
Standards Branch, Division of Laboratory
Science and Standards, Laboratory Science,
Policy and Practice Program Office
(LSPPPO), Office of Surveillance,
Epidemiology and Laboratory Services, CDC,
1600 Clifton Road, NE., Mailstop F–11,
Atlanta, Georgia 30333; telephone (404) 498–
2741; fax (404) 498–2219; or via e-mail at
Nancy.Anderson@cdc.hhs.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
the Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Dated: June 30, 2011.
Elizabeth Millington,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2011–17009 Filed 7–6–11; 8:45 am]
39879
Control and Prevention (CDC)
announces the aforementioned meeting:
Times and Dates: 8 a.m.–7 p.m., July 22,
2011 (Closed).
Place: Corporate Square, Building 8,
Atlanta, Georgia 30333.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘HIV Prevention Projects for
Young Men of Color Who Have Sex with Men
and Young Transgender Persons of Color,
FOA PS11–1113.’’ This subsequent meeting
to the July 10–13, 2011 meeting published in
the Federal Register on February 22, 2011,
Volume 76, Number 35, Pages 9785–9786 has
been scheduled due to the high volume of
applications received and unanticipated
scheduling conflicts for a significant number
of the appointed reviewers.
Contact Person for More Information:
Harriette Lynch, Public Health Analyst,
Extramural Programs, National Center for
HIV, Hepatitis and Sexually Transmitted
Diseases Prevention, CDC, 1600 Clifton Road,
NE., Mailstop E–60, Atlanta, Georgia 30333,
Telephone (404) 498–2726, E-mail
HLynch@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Dated: June 30, 2011.
Elizabeth Millington,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2011–17008 Filed 7–6–11; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns Human Immunodeficiency
Virus (HIV) Prevention Projects for
Young Men of Color Who Have Sex with
Men and Young Transgender Persons of
Color, Funding Opportunity
Announcement (FOA) PS11–1113,
initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
Request for Nominations of
Candidates To Serve on the Board of
Scientific Counselors, National Center
for Environmental Health/Agency for
Toxic Substances and Disease
Registry (BSC, NCEH/ATSDR), Centers
for Disease Control and Prevention,
Department of Health and Human
Services (HHS)
The NCEH/ATSDR is soliciting
nominations for consideration of
membership on the BSC. The BSC,
NCEH/ATSDR provides advice and
guidance to the Secretary, HHS; the
Director, CDC; and the Director, NCEH/
E:\FR\FM\07JYN1.SGM
07JYN1
]]>Agencies
[Federal Register Volume 76, Number 130 (Thursday, July 7, 2011)]
[Notices]
[Page 39879]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-17009]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee (CLIAC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting of the aforementioned
committee:
Times and Dates: 8:30 a.m.-5 p.m., August 31, 2011.
8:30 a.m.-12 p.m., September 1, 2011.
Place: CDC, 1600 Clifton Road, NE., Tom Harkin Global
Communications Center, Building 19, Room 232, Auditorium B, Atlanta,
Georgia 30333.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services, the Assistant Secretary for Health, and the Director, CDC,
regarding the need for, and the nature of, revisions to the
standards under which clinical laboratories are regulated; the
impact on medical and laboratory practice of proposed revisions to
the standards; and the modification of the standards to accommodate
technological advances.
Matters to be Discussed: The agenda will include agency updates
from the CDC, the Centers for Medicare & Medicaid Services (CMS),
and the Food and Drug Administration (FDA); presentations and
discussions on the laboratory's role in the development and use of
electronic health records, electronic laboratory reporting for
notifiable diseases, and meaningful use; and presentations and
discussion on current practices in gynecologic cytology testing.
Agenda items are subject to change as priorities dictate.
Online Registration Required: In order to expedite the security
clearance process at the CDC Roybal Campus located on Clifton Road,
all CLIAC attendees are required to register for the meeting online
at least 14 days in advance at https://www.cdc.gov/cliac/default.aspx
by clicking the ``Register for a Meeting'' link and completing all
forms according to the instructions given. Please complete all the
required fields before submitting your registration and submit no
later than August 16, 2011.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments whenever possible. Oral Comments: In general, each
individual or group requesting to make an oral presentation will be
limited to a total time of five minutes (unless otherwise
indicated). Speakers must also submit their comments in writing for
inclusion in the meeting's Summary Report. To assure adequate time
is scheduled for public comments, individuals or groups planning to
make an oral presentation should, when possible, notify the contact
person below at least one week prior to the meeting date. Written
Comments: For individuals or groups unable to attend the meeting,
CLIAC accepts written comments until the date of the meeting (unless
otherwise stated); however, it is requested that comments be
submitted at least one week prior to the meeting date so that the
comments may be made available to the Committee for their
consideration and public distribution. Written comments, one hard
copy with original signature, should be provided to the contact
person below. Written comments will be included in the meeting's
Summary Report.
Contact Person for Additional Information: Nancy Anderson,
Chief, Laboratory Practice Standards Branch, Division of Laboratory
Science and Standards, Laboratory Science, Policy and Practice
Program Office (LSPPPO), Office of Surveillance, Epidemiology and
Laboratory Services, CDC, 1600 Clifton Road, NE., Mailstop F-11,
Atlanta, Georgia 30333; telephone (404) 498-2741; fax (404) 498-
2219; or via e-mail at Nancy.Anderson@cdc.hhs.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining
to announcements of meetings and other committee management
activities, for the Centers for Disease Control and Prevention, and
the Agency for Toxic Substances and Disease Registry.
Dated: June 30, 2011.
Elizabeth Millington,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2011-17009 Filed 7-6-11; 8:45 am]
BILLING CODE 4163-18-P
